Critical Limb Ischemia is the condition with chronic ischemic at-rest pain that may progressively lead to severe skin ulcers, gangrene, or limb loss. The condition is typically related to the objectively proven severe blockage in the artery. The disease implies, chronicity and is usually associated with multiple sites of arterial obstruction that severely reduced blood flow to the tissues. The disease is clinically manifested as rest pain, non healing wounds and/or tissue necrosis.

Ischemic pain can be associated with the burning sensation in the ball of the foot and toes, which can be worsened at night may be because of the loss of gravity assisted flow to the foot. In the past few years the most significant change in critical lung ischemia treatment has been the increasing tendency to shift from bypass surgery to less invasive stem cell therapy for critical lung ischemia as first-choice causing revascularization of the damaged tissue and removal of plaque deposits to a certain extent.

Symptoms

Major Manifestations of CLI, in patients include the following:

Stem Cells Therapy for Critical Lung Ischemia Treatment: Advancells Protocol

Stem cell treatment at Advancells involves exploitation of the most potent stem cells isolated from patients own Bone marrow or Adipose tissue or may be both depending upon the assessment. Our top priority is to provide very comprehensive, individualized treatment pattern which is best suited for the patients undergoing stem cell treatment for critical lung ischemia. With extensive research these challenges are now comprehensible to therapeutic ventures resulting in new treatments of critical lung ischemia using autologous treatment/allogenic transplant for adipose-derived mesenchymal stromal cells treatment and bone marrow stromal cells treatment. This new insight on the treatment of critical lung ischemia has helped in identifying the potential to overcome critical lung ischemia with stem cells, primarily using autologous stem cell transplant in form of hematopoietic stem cell transplant or mesenchymal stromal cells treatment.